詳細検索

詳細検索

×

キーワード検索の使い方

×
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
日

お問い合わせ

mRNAがんワクチン市場レポート：2026-2036

mRNAがんワクチン市場レポート：2026-2036


mRNA Cancer Vaccine Market Report 2026-2036

説明 Visiongainは新たなレポートを発表しました。 mRNAがんワクチン市場レポート 2026-2036 、世界のmRNAがんワクチン市場について、市場規模、成長要因、競合状況、主要セグメントごとの売上予測な... もっと見る

　

　

出版社
Visiongain
ヴィジョンゲイン社
出版年月
2026年4月21日
電子版価格
Eur5,150
部署ライセンス
ライセンス・価格情報／注文方法はこちら
納期
2営業日程度
ページ数
289
言語
英語

※上記価格は部署ライセンス（Departmental licence）価格です。
その他の価格についてはデータリソースまでお問合せください。
日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。


　

サマリー

説明

Visiongainは新たなレポートを発表しました。mRNAがんワクチン市場レポート 2026-2036、世界のmRNAがんワクチン市場について、市場規模、成長要因、競合状況、主要セグメントごとの売上予測などを網羅的に分析しています。

世界のmRNAがんワクチン市場は、2026年に1,200.0百万米ドルを超えると予想されており、精密腫瘍学の普及拡大、シーケンシング技術の進歩、および臨床開発パイプラインの拡大を背景に、2036年まで堅調な成長が続くと見込まれています。

この成長は、mRNAプラットフォームが腫瘍ゲノミクスに基づいた個別化・標的型免疫療法を可能にする能力に加え、ネオ抗原の同定および送達技術における継続的な革新によって支えられています。

市場拡大を牽引する技術革新

ゲノムシーケンシングおよびネオ抗原予測技術の進歩により、個別化mRNAがんワクチンの開発が加速しています。これらの技術により、腫瘍特異的な変異を正確に標的とすることが可能となり、治療効果の向上や、精密腫瘍学のワークフローへの統合が促進されています。

同時に、自己増幅型mRNAや改良された送達システムといったプラットフォームの革新により、スケーラビリティが向上し、開発期間が短縮されており、mRNAワクチンは次世代のがん治療における主要な治療法としての地位を確立しつつある。

貿易、政策、およびサプライチェーンの動向

mRNAがんワクチン市場は、世界的な貿易の動向、規制の枠組み、およびサプライチェーンへの依存関係によって、ますますその様相を形作られつつある。

生産には、世界中から調達される脂質ナノ粒子、ヌクレオチド、酵素などの特殊な原材料が不可欠です。関税や貿易制限により、コストが上昇したりサプライチェーンが混乱したりする可能性があり、開発スケジュールや価格設定に影響を及ぼす恐れがあります。

同時に、規制要件や国境を越えた連携は、臨床開発や商業化において極めて重要な役割を果たしており、市場へのアクセスや市場投入までのスピードに影響を与えています。

商業的影響

  • コストと価格面での圧力：原材料費や製造コストの上昇が、治療の経済的負担に影響を与える可能性がある
  • サプライチェーンの変容：地域における製造と調達におけるレジリエンスへの注目が高まっている
  • 規制の影響：承認プロセスとコンプライアンスが開発スケジュールを左右する
  • 競合優位性：拡張性の高いプラットフォームと強固なパートナーシップを持つ企業の方が、より有利な立場にある

企業情報

mRNAがんワクチン市場は、確立されたバイオテクノロジー業界のリーダー企業と、新興の革新企業が混在しており、プラットフォームの能力、臨床開発の進捗、戦略的提携の面で競い合っているのが特徴です。

BioNTech、Moderna、Arcturus Therapeutics、Sana Biotechnologyといった主要企業は、臨床開発、プラットフォームの革新、および提携を通じて、その地位を確立しつつある。

競争は、ますます次のような要素によって特徴づけられるようになっている：

  • 技術とプラットフォームの差別化
  • 臨床パイプラインの強み
  • 製造能力と拡張性
  • 戦略的パートナーシップおよび提携

本レポートでは、競争上のポジショニングがどのように変化しているかを分析し、価値がどこで創出されているか、また予測期間中に戦略がどのように変化すると予想されるかを明らかにしています。

主な疑問への回答

  • mRNAがんワクチン市場はどのように変化しているのでしょうか？
  • 市場の成長を後押ししている要因と、その成長を阻んでいる要因は何でしょうか？
  • どのセグメントや地域が最も多くの収益を生み出すでしょうか？
  • 貿易、政策、サプライチェーンの動向は、市場にどのような影響を与えるのでしょうか？
  • 主要企業はどこか、またその見通しはどうか？

報告書の範囲およびデータの対象範囲

  • 世界のmRNAがんワクチン市場分析
  • 2036年までの売上高予測
  • ワクチンの種類、治療アプローチ、臨床試験の段階、適応症、およびエンドユーザーにわたるセグメントレベルのモデリング
  • 地域別および全国市場の予測
  • 主要企業に関する競合情報

定量的な予測と定性的な戦略分析の両方を含み、技術、競合、政策、サプライチェーンの動向を網羅しています。

セグメンテーションの枠組み

ワクチンタイプ別

  • パーソナライズされた
  • セミ・パーソナライズ
  • 市販品

治療アプローチ別

  • 単剤療法
  • 併用療法

フェーズ別

  • フェーズI
  • フェーズII
  • フェーズIII
  • フェーズIV

適応別

  • TMB値の高い固形がん
  • 消化器がん
  • 婦人科がん
  • 乳がん
  • その他の固形がん

エンドユーザー別

  • バイオ医薬品・バイオテクノロジー企業
  • 医薬品開発製造受託機関（CDMO）
  • 研究機関・学術機関
  • 病院・がん専門センター

対象地域

北米

  • アメリカ
  • カナダ

欧州

  • ドイツ
  • イギリス
  • フランス
  • イタリア
  • スペイン
  • その他の欧州地域

アジア太平洋地域

  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • その他のアジア太平洋地域

ラテンアメリカ

  • ブラジル
  • メキシコ
  • その他のラテンアメリカ

中東・アフリカ

  • GCC
  • 南アフリカ
  • その他のMEA地域

mRNAがんワクチン市場レポート 2026-2036

企業インテリジェンスの対象範囲

本レポートには、以下のような主要企業の詳細なプロフィールが掲載されています：

  • Acuitas
  • Arcturus Therapeutics
  • BioNTech
  • Cartesian Therapeutics Inc
  • Chimeron Bio
  • eTheRNA
  • Ethris GmbH
  • ImmuneSensor Therapeutics
  • Moderna
  • Orna Therapeutics
  • Replimune Group
  • Sana Biotechnology
  • ST Pharm
  • Strand Therapeutics

各プロフィールには以下の内容が含まれています：

  • 事業概要
  • 財務および市場における位置づけ
  • 製品および技術力
  • 戦略的展望

特注のインテリジェンスとカスタマイズ

Visiongainは、クライアントの特定のニーズに合わせたインテリジェンスやアドバイザリー・サポートも提供しています。

これには以下が含まれます：

  • カスタマイズされた市場セグメンテーションと予測
  • 競合他社とのベンチマークおよび戦略分析
  • 政策および規制の影響評価
  • サプライチェーンおよび調達インテリジェンス
  • 関税や地政学的リスクを含むシナリオ・モデリング

なぜこの市場インテリジェンスが重要なのか

  • mRNAがんワクチン市場は、精密医療、技術革新、そして世界的な供給動向の変化に後押しされ、急速に進化しています。
  • こうしたトレンドを理解している組織は、成長の機会を捉え、リスクを管理し、競争力を強化する上で、より有利な立場に立つことができるでしょう。


お問い合わせ

お問合せ種類／内容 *

補足が有ればご記入ください
貴社名*
ご担当者名 * 姓 名
メールアドレス *

ページTOPに戻る


目次

1 レポートの概要
1.1 本調査の目的
1.2 mRNAがんワクチン市場の概要
1.3 本レポートの内容
1.4 本レポートを読むべき理由
1.5 本分析レポートが解明する重要な疑問
1.6 本レポートの対象読者
1.7 調査方法
1.7.1 市場の定義
1.7.2 市場評価および予測の方法
1.7.3 データの検証
1.7.3.1 一次調査
1.7.3.2 二次調査
1.8 よくある質問（FAQ）
1.9 関連するVisiongainレポート
1.10 Visiongainについて

2 概要

3 市場の概要
3.1 主な調査結果
3.2 市場の動向
3.3 影響分析
3.3.1 市場を牽引する要因
3.3.1.1 後期臨床試験による検証が商業的な信頼感を高めている
3.3.1.2 がん治療薬専用の製造および自動化のスケールアップ
3.3.1.3 大手製薬企業との戦略的提携および資本投入
3.3.2 市場の抑制要因
3.3.2.1 個別化ワクチンワークフローの運用上の複雑さ
3.3.2.2 新規オンコロジープラットフォームに関する規制および償還の不確実性
3.3.2.3 既存および新興の免疫療法の競争環境
3.3.3 市場機会
3.3.3.1 がん治療の早期段階および補助療法分野への拡大
3.3.3.2 複数の腫瘍タイプにわたるプラットフォームの汎用性
3.3.3.3 mRNAがん治療エコシステムの強化とインフラ投資
3.4 米国の関税：世界のmRNAがんワクチン市場への影響は？
3.4.1 概要
3.4.2 V字型回復シナリオ
3.4.2.1 なぜV字型回復なのか？
3.4.2.2 関税による影響
3.4.2.3 市場の動向と需要の回復
3.4.2.4 政策および資金支援
3.4.3 U字型回復シナリオ
3.4.3.1 なぜU字型回復なのか？
3.4.3.2 関税による影響
3.4.3.3 回復までの期間
3.4.3.4 政策および資金支援
3.4.4 L字型回復シナリオ
3.4.4.1 なぜL字型回復なのか？
3.4.4.2 関税の影響
3.4.4.3 市場の動向と需要の回復
3.4.4.4 政策および資金支援
3.4.5 顧客は短期（2026～2031年）および長期（2026～2036年）の計画において、どのような戦略的考慮事項を織り込むべきか？
3.4.6 米中貿易戦争がmRNAがんワクチン市場に与える影響
3.4.7 最も影響を受ける国々は、これらの政策変更によってどのようなプラスおよびマイナスの影響を受ける可能性があるか？
3.4.8 世界市場における関税感応度および利益率圧迫の分析
3.5 ポーターの5つの力分析
3.5.1 供給者の交渉力
3.5.2 購入者の交渉力
3.5.3 競合他社間の競争
3.5.4 代替品の脅威
3.5.5 新規参入の脅威
3.6 PEST分析

4. mRNAがんワクチン市場分析：適応症別
4.1 主な調査結果
4.2 適応症別セグメント：市場魅力度指数
4.3 適応症別のmRNAがんワクチン市場規模の推定と予測
4.4 TMB値の高い固形がん
4.4.1 地域別市場規模、2026年～2036年（百万米ドル）
4.4.2 地域別市場シェア、2026年および2036年（％）
4.5 消化器系がん
4.5.1 地域別市場規模、2026年～2036年（百万米ドル）
4.5.2 地域別市場シェア、2026年および2036年（％）
4.6 婦人科がん
4.6.1 地域別市場規模、2026年～2036年（百万米ドル）
4.6.2 地域別市場シェア、2026年および2036年（％）
4.7 乳がん
4.7.1 地域別市場規模、2026年～2036年（百万米ドル）
4.7.2 地域別市場シェア、2026年および2036年（％）
4.8 その他の固形がん
4.8.1 地域別市場規模、2026年～2036年（百万米ドル）
4.8.2 地域別市場シェア、2026年および2036年（％）

5. mRNAがんワクチン市場分析：プラットフォーム別
5.1 主な調査結果
5.2 プラットフォーム種別セグメント市場魅力度指数
5.3 プラットフォーム種別によるmRNAがんワクチン市場規模の推定と予測
5.4 個別化
5.4.1 地域別市場規模、2026年～2036年（百万米ドル）
5.4.2 地域別市場シェア、2026年および2036年（％）
5.5 既製
5.5.1 地域別市場規模、2026年～2036年（百万米ドル）
5.5.2 地域別市場シェア、2026年および2036年（％）
5.6 セミパーソナライズ型
5.6.1 地域別市場規模、2026年～2036年（百万米ドル）
5.6.2 地域別市場シェア、2026年および2036年（％）

6. mRNAがんワクチン市場の分析：治療アプローチ別
6.1 主な調査結果
6.2 治療アプローチ別セグメント：市場魅力度指数
6.3 治療アプローチ別のmRNAがんワクチン市場規模の推定と予測
6.4 単剤療法
6.4.1 地域別市場規模、2026年～2036年（百万米ドル）
6.4.2 地域別市場シェア、2026年および2036年（％）
6.5 併用療法
6.5.1 地域別市場規模、2026年～2036年（百万米ドル）
6.5.2 地域別市場シェア、2026年および2036年（％）

7. mRNAがんワクチン市場分析：フェーズ別
7.1 主な調査結果
7.2 フェーズ別セグメント市場魅力度指数
7.3 フェーズ別のmRNAがんワクチン市場規模の推定と予測
7.4 第I相
7.4.1 地域別市場規模、2026年～2036年（百万米ドル）
7.4.2 地域別市場シェア、2026年および2036年（％）
7.5 第II相
7.5.1 地域別市場規模、2026年～2036年（百万米ドル）
7.5.2 地域別市場シェア、2026年および2036年（％）
7.6 フェーズIII
7.6.1 地域別市場規模、2026年～2036年（百万米ドル）
7.6.2 地域別市場シェア、2026年および2036年（％）
7.7 フェーズIV
7.7.1 地域別市場規模、2026年～2036年（百万米ドル）
7.7.2 地域別市場シェア、2029年および2036年（％）

8. mRNAがんワクチン市場分析：エンドユーザー別
8.1 主な調査結果
8.2 エンドユーザー別セグメント：市場魅力度指数
8.3 エンドユーザー別のmRNAがんワクチン市場規模の推定と予測
8.4 バイオ医薬品・バイオテクノロジー企業
8.4.1 地域別市場規模、2026年～2036年（百万米ドル）
8.4.2 地域別市場シェア、2026年および2036年（％）
8.5 受託開発・製造機関（CDMO）
8.5.1 地域別市場規模、2026年～2036年（百万米ドル）
8.5.2 地域別市場シェア、2026年および2036年（％）
8.6 研究機関および学術センター
8.6.1 地域別市場規模、2026年～2036年（百万米ドル）
8.6.2 地域別市場シェア、2026年および2036年（％）
8.7 病院および専門がんセンター
8.7.1 地域別市場規模、2026年～2036年（百万米ドル）
8.7.2 地域別市場シェア、2026年および2036年（％）

9. mRNAがんワクチン市場分析：地域別
9.1 主な調査結果
9.2 地域別市場規模の推計と予測

10 北米のmRNAがんワクチン市場分析
10.1 主な調査結果
10.2 北米mRNAがんワクチン市場の魅力度指数
10.3 北米mRNAがんワクチン市場：国別、2026年、2031年、2036年（百万米ドル）
10.4 北米mRNAがんワクチン市場規模の推定と予測：国別
10.5 北米mRNAがんワクチン市場規模の推定と予測：適応症別
10.6 北米mRNAがんワクチン市場規模の推定と予測：プラットフォームタイプ別
10.7 北米mRNAがんワクチン市場規模の推定と予測：治療アプローチ別
10.8 北米mRNAがんワクチン市場規模の推定と予測：フェーズ別
10.9 北米mRNAがんワクチン市場規模の推定と予測：エンドユーザー別
10.10 米国mRNAがんワクチン市場分析
10.11 カナダmRNAがんワクチン市場分析

11 欧州のmRNAがんワクチン市場分析
11.1 主な調査結果
11.2 欧州のmRNAがんワクチン市場の魅力度指数
11.3 欧州のmRNAがんワクチン市場：国別、2026年、2031年、2036年（百万米ドル）
11.4 欧州mRNAがんワクチン市場規模の推定と予測：国別
11.5 欧州mRNAがんワクチン市場規模の推定と予測：適応症別
11.6 欧州mRNAがんワクチン市場規模の推定と予測：プラットフォームタイプ別
11.7 欧州mRNAがんワクチン市場規模の推定と予測：治療アプローチ別
11.8 欧州mRNAがんワクチン市場規模の推定と予測：フェーズ別
11.9 欧州mRNAがんワクチン市場規模の推定と予測：エンドユーザー別
11.10 ドイツのmRNAがんワクチン市場分析
11.11 フランスのmRNAがんワクチン市場分析
11.12 英国のmRNAがんワクチン市場分析
11.13 イタリアのmRNAがんワクチン市場分析
11.14 スペインのmRNAがんワクチン市場分析
11.15 その他の欧州地域のmRNAがんワクチン市場分析

12 アジア太平洋地域のmRNAがんワクチン市場分析
12.1 主な調査結果
12.2 アジア太平洋地域のmRNAがんワクチン市場の魅力度指数
12.3 アジア太平洋地域のmRNAがんワクチン市場：国別、2026年、2031年、2036年）（百万米ドル）
12.4 アジア太平洋地域のmRNAがんワクチン市場規模の推定と予測：国別
12.5 アジア太平洋地域のmRNAがんワクチン市場規模の推定と予測：適応症別
12.6 アジア太平洋地域のmRNAがんワクチン市場規模の推定と予測：プラットフォームタイプ別
12.7 アジア太平洋地域のmRNAがんワクチン市場規模の推定と予測：治療アプローチ別
12.8 アジア太平洋地域のmRNAがんワクチン市場規模の推定と予測：フェーズ別
12.9 アジア太平洋地域のmRNAがんワクチン市場規模の推定と予測：エンドユーザー別
12.10 日本のmRNAがんワクチン市場分析
12.11 中国のmRNAがんワクチン市場分析
12.12 インドのmRNAがんワクチン市場分析
12.13 オーストラリアのmRNAがんワクチン市場分析
12.14 韓国のmRNAがんワクチン市場分析
12.15 その他のアジア太平洋地域のmRNAがんワクチン市場分析

13 ラテンアメリカのmRNAがんワクチン市場分析
13.1 主な調査結果
13.2 ラテンアメリカmRNAがんワクチン市場の魅力度指数
13.3 ラテンアメリカmRNAがんワクチン市場：国別、2026年、2031年、2036年（百万米ドル）
13.4 ラテンアメリカmRNAがんワクチン市場の規模推定と予測：国別
13.5 ラテンアメリカmRNAがんワクチン市場の規模推定と予測：適応症別
13.6 ラテンアメリカmRNAがんワクチン市場の規模推定と予測：プラットフォームタイプ別
13.7 ラテンアメリカmRNAがんワクチン市場の規模推定と予測：治療アプローチ別
13.8 ラテンアメリカmRNAがんワクチン市場の規模推定と予測：フェーズ別
13.9 ラテンアメリカmRNAがんワクチン市場の規模推定と予測：エンドユーザー別
13.10 ブラジルmRNAがんワクチンの市場分析
13.11 メキシコmRNAがんワクチンの市場分析
13.12 その他のラテンアメリカ地域のmRNAがんワクチンの市場分析

14 MEAのmRNAがんワクチン市場の分析
14.1 主な調査結果
14.2 MEAのmRNAがんワクチン市場の魅力度指数
14.3 MEAのmRNAがんワクチン市場：国別、2026年、2031年、2036年（百万米ドル）
14.4 MEAのmRNAがんワクチン市場規模の推定と予測：国別
14.5 MEAのmRNAがんワクチン市場規模の推定と予測：適応症別
14.6 MEAのmRNAがんワクチン市場規模の推定と予測：プラットフォームタイプ別
14.7 MEAのmRNAがんワクチン市場規模の推定と予測：治療アプローチ別
14.8 MEAのmRNAがんワクチン市場規模の推定と予測：フェーズ別
14.9 MEAのmRNAがんワクチン市場規模の推定と予測：エンドユーザー別
14.10 GCCにおけるmRNAがんワクチン市場分析
14.11 南アフリカにおけるmRNAがんワクチン市場分析
14.12 その他のMEA地域のmRNAがんワクチン市場分析

15 主要企業のプロフィール
15.1 2026年の競争環境
15.2 戦略的展望
15.3 モデルナ社
15.3.1 企業概要
15.3.2 会社概要
15.3.3 財務分析
15.3.3.1 純売上高（2021年～2025年）
15.3.3.2 研究開発費（2021年～2025年）
15.3.3.3 地域別市場シェア（2025年）
15.3.3.4 事業セグメント別市場シェア（2025年）
15.3.4 製品ベンチマーク
15.3.5 SWOT分析
15.3.6 戦略的展望
15.4 BioNTech SE
15.4.1 企業概要
15.4.2 会社概要
15.4.3 財務分析
15.4.3.1 純売上高（2021年～2025年）
15.4.3.2 研究開発費（R&D）、2021年～2025年
15.4.4 製品ベンチマーク
15.4.5 SWOT分析
15.4.6 戦略的展望
15.5 Arcturus Therapeutics, Inc.
15.5.1 企業概要
15.5.2 会社概要
15.5.3 財務分析
15.5.3.1 純売上高（2021年～2025年）
15.5.3.2 研究開発費（2021年～2025年）
15.5.3.3 事業セグメント別市場シェア（2025年）
15.5.4 製品ベンチマーク
15.5.5 SWOT分析
15.5.6 戦略的展望
15.6 etherna
15.6.1 企業概要
15.6.2 会社概要
15.6.3 製品ベンチマーク
15.6.4 SWOT分析
15.6.5 戦略的展望
15.7 ETHRIS
15.7.1 企業概要
15.7.2 会社概要
15.7.3 製品ベンチマーク
15.7.4 戦略的展望
15.8 ImmmuneSensor Therapeutics
15.8.1 企業概要
15.8.2 会社概要
15.8.3 製品ベンチマーク
15.8.4 戦略的展望
15.9 Chimeron Bio
15.9.1 企業概要
15.9.2 会社概要
15.9.3 製品ベンチマーク
15.9.4 戦略的展望
15.10 Replimune Group Inc.
15.10.1 会社概要
15.10.2 会社概要
15.10.3 製品ベンチマーク
15.11 STファーム
15.11.1 企業概要
15.11.2 会社概要
15.11.3 製品ベンチマーク
15.11.4 戦略的展望
15.12 サナ・バイオテクノロジー
15.12.1 企業概要
15.12.2 会社概要
15.12.3 製品ベンチマーク
15.13 カルテシアン・セラピューティクス社
15.13.1 企業概要
15.13.2 会社概要
15.13.3 財務分析
15.13.3.1 純売上高（2021年～2025年）
15.13.3.2 研究開発費（2021年～2025年）
15.13.4 製品ベンチマーク
15.14 Strand Therapeutics
15.14.1 企業概要
15.14.2 会社概要
15.14.3 製品ベンチマーク
15.14.4 戦略的展望
15.15 アクイタス
15.15.1 企業概要
15.15.2 会社概要
15.15.3 製品ベンチマーク
15.15.4 戦略的展望

16 結論と提言
16.1 Visiongainによる総括
16.2 市場関係者への提言

 

ページTOPに戻る



図表リスト

List of Tables
Table 1 mRNA Cancer Vaccine Market Snapshot, 2026 & 2036 (US$ Million, CAGR %)
Table 2 mRNA Cancer Vaccine Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 3 mRNA Cancer Vaccine Market Forecast by Region 2026-2036 (US$ Million, AGR%, CAGR%), Tariff Impact: U- Shaped Recovery Scenario
Table 4 mRNA Cancer Vaccine Market Forecast by Region 2026-2036 (US$ Million, AGR%, CAGR%), Tariff Impact: L- Shaped Recovery Scenario
Table 5 mRNA Cancer Vaccine Market Forecast by Indication, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 6 High TMB Solid Tumors Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 7 GI Cancers Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 8 Gynecological Cancers Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 9 Breast Cancers Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 10 Other Sollid Tumors Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 11 mRNA Cancer Vaccine Market Forecast by Platform Type, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 12 Personalized Market Forecast by Platform Type, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 13 Off-the-Shelf Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 14 Semi-Personalized Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 15 mRNA Cancer Vaccine Market Forecast by Therapeutic Approach, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 16 Monotherapy Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 17 Combination Therapy Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 18 mRNA Cancer Vaccine Market Forecast by Phases, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 19 Phase I Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 20 Phase II Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 21 mRNA Cancer Vaccine Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 22 Phase IV Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 23 mRNA Cancer Vaccine Market Forecast by End Users, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 24 Biopharma & Biotechnology Companies Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 25 Contract Development & Manufacturing Organizations (CDMOs) Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 26 Research Institutes & Academic Centers Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 27 Hospitals & Specialized Cancer Centers Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 28 mRNA Cancer Vaccine Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 29 North America mRNA Cancer Vaccine Market Forecast by Country, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 30 North America mRNA Cancer Vaccine Market Forecast by Indication, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 31 North America mRNA Cancer Vaccine Market Forecast by Platform Type, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 32 North America mRNA Cancer Vaccine Market Forecast by Therapeutic Approach, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 33 North America mRNA Cancer Vaccine Market Forecast by Phases, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 34 North America mRNA Cancer Vaccine Market Forecast by End Users, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 35 U.S. mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 36 Canada mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 37 Europe mRNA Cancer Vaccine Market Forecast by Country, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 38 Europe mRNA Cancer Vaccine Market Forecast by Indication, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 39 Europe mRNA Cancer Vaccine Market Forecast by Platform Type, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 40 Europe mRNA Cancer Vaccine Market Forecast by Therapeutic Approach, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 41 Europe mRNA Cancer Vaccine Market Forecast by Phases, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 42 Europe mRNA Cancer Vaccine Market Forecast by End Users, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 43 Germany mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 44 France mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 45 UK mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 46 Italy mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 47 Spain mRNA Cancer Vaccine Market Forecast by Country, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 48 Rest of Europe mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 49 Asia Pacific mRNA Cancer Vaccine Market Forecast by Country, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 50 Asia Pacific mRNA Cancer Vaccine Market Forecast by Indication, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 51 Asia Pacific mRNA Cancer Vaccine Market Forecast by Platform Type, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 52 Asia Pacific mRNA Cancer Vaccine Market Forecast by Therapeutic Approach, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 53 Asia Pacific mRNA Cancer Vaccine Market Forecast by Phases, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 54 Asia Pacific mRNA Cancer Vaccine Market Forecast by End Users, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 55 Japan mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 56 China mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 57 India mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 58 Australia mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 59 South Korea mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 60 Rest of Asia Pacific mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 61 Latin America mRNA Cancer Vaccine Market Forecast by Country, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 62 Latin America mRNA Cancer Vaccine Market Forecast by Indication, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 63 Latin America mRNA Cancer Vaccine Market Forecast by Platform Type, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 64 Latin America mRNA Cancer Vaccine Market Forecast by Therapeutic Approach, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 65 Latin America mRNA Cancer Vaccine Market Forecast by Phases, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 66 Latin America mRNA Cancer Vaccine Market Forecast by End Users, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 67 Brazil mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 68 Mexico mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 69 Rest of Latin America mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 70 MEA mRNA Cancer Vaccine Market Forecast by Country, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 71 MEA mRNA Cancer Vaccine Market Forecast by Indication, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 72 MEA mRNA Cancer Vaccine Market Forecast by Platform Type, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 73 MEA mRNA Cancer Vaccine Market Forecast by Therapeutic Approach, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 74 MEA mRNA Cancer Vaccine Market Forecast by Phases, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 75 MEA mRNA Cancer Vaccine Market Forecast by End Users, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 76 GCC mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 77 South Africa mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 78 Rest of MEA mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 79 Strategic Outlook
Table 80 Moderna, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 81 Moderna, Inc.: Product Benchmarking
Table 82 Moderna, Inc.: SWOT Analysis
Table 83 Moderna, Inc.: Strategic Outlook
Table 84 BioNTech SE: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 85 BioNTech SE: Product Benchmarking
Table 86 BioNtech SE: SWOT Analysis
Table 87 BioNTech SE: Strategic Outlook
Table 88 Arcturus Therapeutics, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 89 Arcturus Therapeutics, Inc.: Product Benchmarking
Table 90 Arcturus Therapeutics, Inc.: SWOT Analysis
Table 91 Arcturus Therapeutics, Inc. : Strategic Outlook
Table 92 etherna: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 93 etherna: Product Benchmarking
Table 94 etherna: SWOT Analysis
Table 95 etherna: Strategic Outlook
Table 96 ETHRIS: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 97 ETHRIS: Product Benchmarking
Table 98 ETHRIS: Strategic Outlook
Table 99 ImmmuneSensor Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 100 ImmmuneSensor Therapeutics: Product Benchmarking
Table 101 ImmmuneSensor Therapeutics: Strategic Outlook
Table 102 Chimeron Bio: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 103 Chimeron Bio: Product Benchmarking
Table 104 Chimeron Bio: Strategic Outlook
Table 105 Replimune Group Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 106 Replimune Group Inc.: Product Benchmarking
Table 107 ST Pharm: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 108 ST Pharm: Product Benchmarking
Table 109 ST Pharm: Strategic Outlook
Table 110 Sana Biotechnology: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 111 Sana Biotechnology: Product Benchmarking
Table 112 Cartesian Therapeutics Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 113 Cartesian Therapeutics Inc.: Product Benchmarking
Table 114 Strand Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 115 Strand Therapeutics: Product Benchmarking
Table 116 Strand Therapeutics: Strategic Outlook
Table 117 Acuitas: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 118 Acuitas: Product Benchmarking
Table 119 Acuitas: Strategic Outlook

List of Figures
Figure 1 mRNA Cancer Vaccine Market Segmentation
Figure 2 mRNA Cancer Vaccine Market by Indication: Market Attractiveness Index
Figure 3 mRNA Cancer Vaccine Market by Platform Type: Market Attractiveness Index
Figure 4 mRNA Cancer Vaccine Market by End Users: Market Attractiveness Index
Figure 5 mRNA Cancer Vaccine Market Attractiveness Index by Region
Figure 6 mRNA Cancer Vaccine Market: Market Dynamics
Figure 7 mRNA Cancer Vaccine Market: Impact Analysis
Figure 8 mRNA Cancer Vaccine Market by Region, 2026-2036 (US$ Million, AGR %), Tariff Impact: V-Shaped Recovery Scenario
Figure 9 mRNA Cancer Vaccine Market by Region, 2026-2036 (US$ Million, AGR %), Tariff Impact: U-Shaped Recovery Scenario
Figure 10 mRNA Cancer Vaccine Market by Region, 2026-2036 (US$ Million, AGR %), Tariff Impact: L-Shaped Recovery Scenario
Figure 11 Short Term & Long Term Planning
Figure 12 Impact of U.S. and China Trade War
Figure 13 Most Impacted Countries
Figure 14 Global Market Tariff Sensitivity and Margin Pressure Analysis
Figure 15 mRNA Cancer Vaccine Market: Porter’s Five Forces Analysis
Figure 16 mRNA Cancer Vaccine Market: PEST Analysis
Figure 17 mRNA Cancer Vaccine Market by Indication: Market Attractiveness Index
Figure 18 mRNA Cancer Vaccine Market Forecast by Indication, 2026-2036 (US$ Million, AGR %)
Figure 19 mRNA Cancer Vaccine Market Share Forecast by Indication, 2026, 2031, 2036 (%)
Figure 20 High TMB Solid Tumors Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 21 High TMB Solid Tumors Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 22 GI Cancers Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 23 GI Cancers Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 24 Gynecological Cancers Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 25 Gynecological Cancers Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 26 Breast Cancers Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 27 Breast Cancers Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 28 Other Solid Tumors Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 29 Other Solid Tumors Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 30 mRNA Cancer Vaccine Market by Platform Type: Market Attractiveness Index
Figure 31 mRNA Cancer Vaccine Market Forecast by Platform Type, 2026-2036 (US$ Million, AGR %)
Figure 32 mRNA Cancer Vaccine Market Share Forecast by Platform Type, 2026, 2031, 2036 (%)
Figure 33 mRNA Cancer Vaccine Market Forecast by Platform Type, 2026-2036 (US$ Million, AGR %)
Figure 34 Personalized Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 35 Off-the-Shelf Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 36 Off-the-Shelf Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 37 Semi-Personalized Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 38 Semi-Personalized Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 39 mRNA Cancer Vaccine Market by Therapeutic Approach: Market Attractiveness Index
Figure 40 mRNA Cancer Vaccine Market Forecast by Therapeutic Approach, 2026-2036 (US$ Million, AGR %)
Figure 41 mRNA Cancer Vaccine Market Share Forecast by Therapeutic Approach, 2026, 2031, 2036 (%)
Figure 42 Monotherapy Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 43 Monotherapy Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 44 Combination Therapy Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 45 Combination Therapy Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 46 mRNA Cancer Vaccine Market by Phases: Market Attractiveness Index
Figure 47 mRNA Cancer Vaccine Market Forecast by Phases, 2026-2036 (US$ Million, AGR %)
Figure 48 mRNA Cancer Vaccine Market Share Forecast by Phases, 2026, 2031, 2036 (%)
Figure 49 Phase I Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 50 Phase I Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 51 Phase II Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 52 Phase II Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 53 Phase III Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 54 Phase III Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 55 Phase IV Segment Market Forecast by Region
Figure 56 Phase IV Segment Market Share Forecast by Region, 2029 & 2036 (%)
Figure 57 mRNA Cancer Vaccine Market by End Users: Market Attractiveness Index
Figure 58 mRNA Cancer Vaccine Market Forecast by End Users, 2026-2036 (US$ Million, AGR %)
Figure 59 mRNA Cancer Vaccine Market Share Forecast by End Users, 2026, 2031, 2036 (%)
Figure 60 Biopharma & Biotechnology Companies Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 61 Biopharma & Biotechnology Companies Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 62 Contract Development & Manufacturing Organizations (CDMOs) Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 63 Contract Development & Manufacturing Organizations (CDMOs) Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 64 Research Institutes & Academic Centers Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 65 Research Institutes & Academic Centers Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 66 Hospitals & Specialized Cancer Centers Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 67 Hospitals & Specialized Cancer Centers Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 68 mRNA Cancer Vaccine Market Forecast by Region 2026 and 2036 (Revenue, CAGR%)
Figure 69 mRNA Cancer Vaccine Market Share Forecast by Region 2026, 2031, 2036 (%)
Figure 70 mRNA Cancer Vaccine Market by Region, 2026-2036 (US$ Million, AGR %)
Figure 71 North America mRNA Cancer Vaccine Market Attractiveness Index
Figure 72 North America mRNA Cancer Vaccine Market by Region, 2026, 2031 & 2036 (US$ Million)
Figure 73 North America mRNA Cancer Vaccine Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
Figure 74 North America mRNA Cancer Vaccine Market Share Forecast by Country, 2026 & 2036 (%)
Figure 75 North America mRNA Cancer Vaccine Market Forecast by Indication, 2026-2036 (US$ Million, AGR %)
Figure 76 North America mRNA Cancer Vaccine Market Share Forecast by Indication, 2026 & 2036 (%)
Figure 77 North America mRNA Cancer Vaccine Market Forecast by Platform Type, 2026-2036 (US$ Million, AGR %)
Figure 78 North America mRNA Cancer Vaccine Market Share Forecast by Platform Type, 2026 & 2036 (%)
Figure 79 North America mRNA Cancer Vaccine Market Forecast by Therapeutic Approach, 2026-2036 (US$ Million, AGR %)
Figure 80 North America mRNA Cancer Vaccine Market Share Forecast by Therapeutic Approach, 2026 & 2036 (%)
Figure 81 North America mRNA Cancer Vaccine Market Forecast by Phases, 2026-2036 (US$ Million, AGR %)
Figure 82 North America mRNA Cancer Vaccine Market Share Forecast by Phases, 2026 & 2036 (%)
Figure 83 North America mRNA Cancer Vaccine Market Forecast by End Users, 2026-2036 (US$ Million, AGR %)
Figure 84 North America mRNA Cancer Vaccine Market Share Forecast by End Users, 2026 & 2036 (%)
Figure 85 U.S. mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 86 Canada mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 87 Europe mRNA Cancer Vaccine Market Attractiveness Index
Figure 88 Europe mRNA Cancer Vaccine Market by Region, 2026, 2031 & 2036 (US$ Million)
Figure 89 Europe mRNA Cancer Vaccine Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
Figure 90 Europe mRNA Cancer Vaccine Market Share Forecast by Country, 2026 & 2036 (%)
Figure 91 Europe mRNA Cancer Vaccine Market Forecast by Indication, 2026-2036 (US$ Million, AGR %)
Figure 92 Europe mRNA Cancer Vaccine Market Share Forecast by Indication, 2026 & 2036 (%)
Figure 93 Europe mRNA Cancer Vaccine Market Forecast by Platform Type, 2026-2036 (US$ Million, AGR %)
Figure 94 Europe mRNA Cancer Vaccine Market Share Forecast by Platform Type, 2026 & 2036 (%)
Figure 95 Europe mRNA Cancer Vaccine Market Forecast by Therapeutic Approach, 2026-2036 (US$ Million, AGR %)
Figure 96 Europe mRNA Cancer Vaccine Market Share Forecast by Therapeutic Approach, 2026 & 2036 (%)
Figure 97 Europe mRNA Cancer Vaccine Market Forecast by Phases, 2026-2036 (US$ Million, AGR %)
Figure 98 Europe mRNA Cancer Vaccine Market Share Forecast by Phases, 2026 & 2036 (%)
Figure 99 Europe mRNA Cancer Vaccine Market Forecast by End Users, 2026-2036 (US$ Million, AGR %)
Figure 100 Europe mRNA Cancer Vaccine Market Share Forecast by End Users, 2026 & 2036 (%)
Figure 101 Germany mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 102 France mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 103 UK mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 104 Italy mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 105 Spain mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 106 Rest of Europe mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 107 Asia Pacific mRNA Cancer Vaccine Market Attractiveness Index
Figure 108 Asia Pacific mRNA Cancer Vaccine Market by Region, 2026, 2031 & 2036 (US$ Million)
Figure 109 Asia Pacific mRNA Cancer Vaccine Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
Figure 110 Asia Pacific mRNA Cancer Vaccine Market Share Forecast by Country, 2026 & 2036 (%)
Figure 111 Asia Pacific mRNA Cancer Vaccine Market Forecast by Indication, 2026-2036 (US$ Million, AGR %)
Figure 112 Asia Pacific mRNA Cancer Vaccine Market Share Forecast by Indication, 2026 & 2036 (%)
Figure 113 Asia Pacific mRNA Cancer Vaccine Market Forecast by Platform Type, 2026-2036 (US$ Million, AGR %)
Figure 114 Asia Pacific mRNA Cancer Vaccine Market Share Forecast by Platform Type, 2026 & 2036 (%)
Figure 115 Asia Pacific mRNA Cancer Vaccine Market Forecast by Therapeutic Approach, 2026-2036 (US$ Million, AGR %)
Figure 116 Asia Pacific mRNA Cancer Vaccine Market Share Forecast by Therapeutic Approach, 2026 & 2036 (%)
Figure 117 Asia Pacific mRNA Cancer Vaccine Market Forecast by Phases, 2026-2036 (US$ Million, AGR %)
Figure 118 Asia Pacific mRNA Cancer Vaccine Market Share Forecast by Phases, 2026 & 2036 (%)
Figure 119 Asia Pacific mRNA Cancer Vaccine Market Forecast by End Users, 2026-2036 (US$ Million, AGR %)
Figure 120 Asia Pacific mRNA Cancer Vaccine Market Share Forecast by End Users, 2026 & 2036 (%)
Figure 121 Japan mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 122 China mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 123 India mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 124 Australia mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 125 South Korea mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 126 Rest of Asia Pacific mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 127 Latin America mRNA Cancer Vaccine Market Attractiveness Index
Figure 128 Latin America mRNA Cancer Vaccine Market by Region, 2026, 2031 & 2036 (US$ Million)
Figure 129 Latin America mRNA Cancer Vaccine Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
Figure 130 Latin America mRNA Cancer Vaccine Market Share Forecast by Country, 2026 & 2036 (%)
Figure 131 Latin America mRNA Cancer Vaccine Market Forecast by Indication, 2026-2036 (US$ Million, AGR %)
Figure 132 Latin America mRNA Cancer Vaccine Market Share Forecast by Indication, 2026 & 2036 (%)
Figure 133 Latin America mRNA Cancer Vaccine Market Forecast by Platform Type, 2026-2036 (US$ Million, AGR %)
Figure 134 Latin America mRNA Cancer Vaccine Market Share Forecast by Platform Type, 2026 & 2036 (%)
Figure 135 Latin America mRNA Cancer Vaccine Market Forecast by Therapeutic Approach, 2026-2036 (US$ Million, AGR %)
Figure 136 Latin America mRNA Cancer Vaccine Market Share Forecast by Therapeutic Approach, 2026 & 2036 (%)
Figure 137 Latin America mRNA Cancer Vaccine Market Forecast by Phases, 2026-2036 (US$ Million, AGR %)
Figure 138 Latin America mRNA Cancer Vaccine Market Share Forecast by Phases, 2026 & 2036 (%)
Figure 139 Latin America mRNA Cancer Vaccine Market Forecast by End Users, 2026-2036 (US$ Million, AGR %)
Figure 140 Latin America mRNA Cancer Vaccine Market Share Forecast by End Users, 2026 & 2036 (%)
Figure 141 Brazil mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 142 Mexico mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 143 Rest of Latin America mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 144 MEA mRNA Cancer Vaccine Market Attractiveness Index
Figure 145 MEA mRNA Cancer Vaccine Market by Region, 2026, 2031 & 2036 (US$ Million)
Figure 146 MEA mRNA Cancer Vaccine Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
Figure 147 MEA mRNA Cancer Vaccine Market Share Forecast by Country, 2026 & 2036 (%)
Figure 148 MEA mRNA Cancer Vaccine Market Forecast by Indication, 2026-2036 (US$ Million, AGR %)
Figure 149 MEA mRNA Cancer Vaccine Market Share Forecast by Indication, 2026 & 2036 (%)
Figure 150 MEA mRNA Cancer Vaccine Market Forecast by Platform Type, 2026-2036 (US$ Million, AGR %)
Figure 151 MEA mRNA Cancer Vaccine Market Share Forecast by Platform Type, 2026 & 2036 (%)
Figure 152 MEA mRNA Cancer Vaccine Market Forecast by Therapeutic Approach, 2026-2036 (US$ Million, AGR %)
Figure 153 MEA mRNA Cancer Vaccine Market Share Forecast by Therapeutic Approach, 2026 & 2036 (%)
Figure 154 MEA mRNA Cancer Vaccine Market Forecast by Phases, 2026-2036 (US$ Million, AGR %)
Figure 155 MEA mRNA Cancer Vaccine Market Share Forecast by Phases, 2026 & 2036 (%)
Figure 156 MEA mRNA Cancer Vaccine Market Forecast by End Users, 2026-2036 (US$ Million, AGR %)
Figure 157 MEA mRNA Cancer Vaccine Market Share Forecast by End Users, 2026 & 2036 (%)
Figure 158 GCC mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 159 South Africa mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 160 Rest of MEA mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 161 mRNA Cancer Vaccine Market: Company Share/Ranking, 2026
Figure 162 Moderna, Inc.: Net Revenue, 2021-2025 (US$ Billion, AGR%)
Figure 163 Moderna, Inc.: R&D, 2021-2025 (US$ Billion, AGR%)
Figure 164 Moderna, Inc.: Regional Market Shares, 2025
Figure 165 Moderna, Inc.: Business Segment Market Shares, 2025
Figure 166 BioNTech SE: Net Revenue, 2021-2025 (US$ Billion, AGR%)
Figure 167 BioNTech SE: R&D, 2021-2025 (US$ Billion, AGR%)
Figure 168 Arcturus Therapeutics, Inc.: Net Revenue, 2021-2025 (US$ Million, AGR%)
Figure 169 Arcturus Therapeutics, Inc.: R&D, 2021-2025 (US$ Million, AGR%)
Figure 170 Arcturus Therapeutics, Inc.: Business Segment Market Shares, 2025
Figure 171 Cartesian Therapeutics Inc.: Net Revenue, 2021-2025 (US$ Million, AGR%)
Figure 172 Cartesian Therapeutics, Inc.: R&D, 2021-2025 (US$ Million, AGR%)

 

　

ページTOPに戻る


　

Summary

Description

Visiongain has published a new report, mRNA Cancer Vaccine Market Report 2026-2036, providing a comprehensive analysis of the global mRNA cancer vaccine market, including market size, growth drivers, competitive positioning, and revenue forecasts across key segments.

The global mRNA cancer vaccine market is expected to surpass US$1,200.0 million in 2026, with strong growth projected through to 2036, driven by increasing adoption of precision oncology, advances in sequencing technologies, and expanding clinical pipelines.

This growth is supported by the ability of mRNA platforms to enable personalised, targeted immunotherapies based on tumour genomics, alongside continued innovation in neoantigen identification and delivery technologies.

Technological Innovation Driving Market Expansion

Advances in genomic sequencing and neoantigen prediction are accelerating the development of personalised mRNA cancer vaccines. These technologies enable precise targeting of tumour-specific mutations, improving therapeutic effectiveness and supporting integration into precision oncology workflows.

At the same time, platform innovations such as self-amplifying mRNA and improved delivery systems are enhancing scalability and reducing development timelines, positioning mRNA vaccines as a key modality in next-generation oncology treatments.

Trade, Policy & Supply Chain Dynamics

The mRNA cancer vaccine market is increasingly shaped by global trade dynamics, regulatory frameworks, and supply chain dependencies.

Production relies on specialised inputs including lipid nanoparticles, nucleotides, and enzymes sourced globally. Tariffs and trade restrictions may increase costs and disrupt supply chains, impacting development timelines and pricing.

In parallel, regulatory requirements and cross-border collaboration play a critical role in clinical development and commercialisation, influencing market access and speed to market.

Commercial Impact

  • Cost and pricing pressure: Rising input and manufacturing costs may impact therapy affordability
  • Supply chain shifts: Increased focus on regional manufacturing and sourcing resilience
  • Regulatory influence: Approval pathways and compliance shape development timelines
  • Competitive positioning: Companies with scalable platforms and strong partnerships are better positioned

Company Intelligence

The mRNA cancer vaccine market is characterised by a mix of established biotechnology leaders and emerging innovators competing across platform capability, clinical progress, and strategic partnerships.

Leading companies including BioNTech, Moderna, Arcturus Therapeutics, and Sana Biotechnology are advancing their positions through clinical development, platform innovation, and collaboration.

Competition is increasingly defined by:

  • Technology and platform differentiation
  • Clinical pipeline strength
  • Manufacturing capability and scalability
  • Strategic partnerships and collaborations

This report analyses how competitive positioning is evolving, identifying where value is being created and how strategies are expected to shift over the forecast period.

Key Questions Answered

  • How is the mRNA cancer vaccine market evolving?
  • What is driving and restraining market growth?
  • Which segments and regions will generate the most revenue?
  • How will trade, policy, and supply chain dynamics impact the market?
  • Who are the leading companies and what are their prospects?

Report Scope and Data Coverage

  • Global mRNA cancer vaccine market analysis
  • Revenue forecasts to 2036
  • Segment-level modelling across vaccine type, therapeutic approach, phase, indication, and end-user
  • Regional and national market forecasts
  • Competitive intelligence on leading companies

Includes both quantitative forecasting and qualitative strategic analysis, covering technology, competition, policy, and supply chain dynamics.

Segmentation Framework

By Vaccine Type

  • Personalised
  • Semi-Personalised
  • Off-the-Shelf

By Therapeutic Approach

  • Monotherapy
  • Combination Therapy

By Phase

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

By Indication

  • High TMB Solid Tumors
  • GI Cancers
  • Gynecological Cancers
  • Breast Cancer
  • Other Solid Tumours

By End-user

  • Biopharma & Biotechnology Companies
  • Contract Development & Manufacturing Organisations (CDMOs)
  • Research Institutes & Academic Centres
  • Hospitals & Specialised Cancer Centres

Geographic Coverage

North America

  • U.S.
  • Canada

Europe

  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia Pacific

  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa

  • GCC
  • South Africa
  • Rest of MEA

mRNA Cancer Vaccine Market Report 2026-2036

Company Intelligence Coverage

This report includes detailed profiles of leading companies such as:

  • Acuitas
  • Arcturus Therapeutics
  • BioNTech
  • Cartesian Therapeutics Inc
  • Chimeron Bio
  • eTheRNA
  • Ethris GmbH
  • ImmuneSensor Therapeutics
  • Moderna
  • Orna Therapeutics
  • Replimune Group
  • Sana Biotechnology
  • ST Pharm
  • Strand Therapeutics

Each profile includes:

  • Business overview
  • Financial and market positioning
  • Product and technology capabilities
  • Strategic outlook

Bespoke Intelligence & Customisation

Visiongain also provides tailored intelligence and advisory support aligned to specific client requirements.

This includes:

  • Custom market segmentation and forecasts
  • Competitive benchmarking and strategy analysis
  • Policy and regulatory impact assessment
  • Supply chain and sourcing intelligence
  • Scenario modelling including tariffs and geopolitical risk

Why This Market Intelligence Matters

  • The mRNA cancer vaccine market is evolving rapidly, driven by precision medicine, technological innovation, and changing global supply dynamics.
  • Organisations that understand these trends will be better positioned to capture growth opportunities, manage risk, and strengthen competitive positioning.


ページTOPに戻る


Table of Contents

1 Report Overview
1.1 Objectives of the Study
1.2 Introduction to mRNA Cancer Vaccine Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report for?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2 Executive Summary

3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.3 Impact Analysis
3.3.1 Market Driving Factors
3.3.1.1 Late-Stage Clinical Validation Strengthening Commercial Confidence
3.3.1.2 Dedicated Oncology Manufacturing and Automation Scale-Up
3.3.1.3 Strategic Big Pharma Alliances and Capital Deployment
3.3.2 Market Restraining Factors
3.3.2.1 Operational Complexity of Individualized Vaccine Workflows
3.3.2.2 Regulatory and Reimbursement Uncertainty for Novel Oncology Platforms
3.3.2.3 Competitive Landscape of Established and Emerging Immunotherapies
3.3.3 Market Opportunities
3.3.3.1 Expansion into Early-Stage and Adjuvant Cancer Settings
3.3.3.2 Platform Replicability Across Multiple Tumor Types
3.3.3.3 Strengthening mRNA Oncology Ecosystem and Infrastructure Investment
3.4 U.S. Tariffs: What’s the Impact on Global mRNA Cancer Vaccine Market?
3.4.1 Overview
3.4.2 V-Shaped Recovery Scenario
3.4.2.1 Why V-Shaped Recovery?
3.4.2.2 Impact from Tariffs
3.4.2.3 Market Dynamics and Demand Recovery
3.4.2.4 Policy and Funding Support
3.4.3 U-Shaped Recovery Scenario
3.4.3.1 Why U-Shaped Recovery?
3.4.3.2 Impact from Tariffs
3.4.3.3 Timeframe for Recovery
3.4.3.4 Policy and Funding Support
3.4.4 L Shaped Recovery Scenario
3.4.4.1 Why L-Shaped Recovery?
3.4.4.2 Impact from Tariffs
3.4.4.3 Market Dynamics and Demand Recovery
3.4.4.4 Policy and Funding Support
3.4.5 What Strategic Considerations Should Clients Factor into Their Near-term (2026–2031) and Long-term (2026–2036) Planning?
3.4.6 Impact of U.S. and China Trade War on mRNA Cancer Vaccine Market
3.4.7 How Might the Most Impacted Countries Experience Positive and Negative Effects Resulting from These Policy Changes?
3.4.8 Global Market Tariff Sensitivity and Margin Pressure Analysis
3.5 Porter’s Five Forces Analysis
3.5.1 Bargaining Power of Suppliers
3.5.2 Bargaining Power of Buyers
3.5.3 Competitive Rivalry
3.5.4 Threat of Substitutes
3.5.5 Threat of New Entrants
3.6 PEST Analysis

4 mRNA Cancer Vaccine Market Analysis by Indication
4.1 Key Findings
4.2 Indication Segment: Market Attractiveness Index
4.3 mRNA Cancer Vaccine Market Size Estimation and Forecast by Indication
4.4 High TMB Solid Tumors
4.4.1 Market Size by Region, 2026-2036 (US$ Million)
4.4.2 Market Share by Region, 2026 & 2036 (%)
4.5 GI Cancers
4.5.1 Market Size by Region, 2026-2036 (US$ Million)
4.5.2 Market Share by Region, 2026 & 2036 (%)
4.6 Gynecological Cancers
4.6.1 Market Size by Region, 2026-2036 (US$ Million)
4.6.2 Market Share by Region, 2026 & 2036 (%)
4.7 Breast Cancers
4.7.1 Market Size by Region, 2026-2036 (US$ Million)
4.7.2 Market Share by Region, 2026 & 2036 (%)
4.8 Other Solid Tumors
4.8.1 Market Size by Region, 2026-2036 (US$ Million)
4.8.2 Market Share by Region, 2026 & 2036 (%)

5 mRNA Cancer Vaccine Market Analysis by Platform Type
5.1 Key Findings
5.2 Platform Type Segment: Market Attractiveness Index
5.3 mRNA Cancer Vaccine Market Size Estimation and Forecast by Platform Type
5.4 Personalized
5.4.1 Market Size by Region, 2026-2036 (US$ Million)
5.4.2 Market Share by Region, 2026 & 2036 (%)
5.5 Off-the-Shelf
5.5.1 Market Size by Region, 2026-2036 (US$ Million)
5.5.2 Market Share by Region, 2026 & 2036 (%)
5.6 Semi-Personalized
5.6.1 Market Size by Region, 2026-2036 (US$ Million)
5.6.2 Market Share by Region, 2026 & 2036 (%)

6 mRNA Cancer Vaccine Market Analysis by Therapeutic Approach
6.1 Key Findings
6.2 Therapeutic Approach Segment: Market Attractiveness Index
6.3 mRNA Cancer Vaccine Market Size Estimation and Forecast by Therapeutic Approach
6.4 Monotherapy
6.4.1 Market Size by Region, 2026-2036 (US$ Million)
6.4.2 Market Share by Region, 2026 & 2036 (%)
6.5 Combination Therapy
6.5.1 Market Size by Region, 2026-2036 (US$ Million)
6.5.2 Market Share by Region, 2026 & 2036 (%)

7 mRNA Cancer Vaccine Market Analysis by Phases
7.1 Key Findings
7.2 Phases Segment: Market Attractiveness Index
7.3 mRNA Cancer Vaccine Market Size Estimation and Forecast by Phases
7.4 Phase I
7.4.1 Market Size by Region, 2026-2036 (US$ Million)
7.4.2 Market Share by Region, 2026 & 2036 (%)
7.5 Phase II
7.5.1 Market Size by Region, 2026-2036 (US$ Million)
7.5.2 Market Share by Region, 2026 & 2036 (%)
7.6 Phase III
7.6.1 Market Size by Region, 2026-2036 (US$ Million)
7.6.2 Market Share by Region, 2026 & 2036 (%)
7.7 Phase IV
7.7.1 Market Size by Region, 2026-2036 (US$ Million)
7.7.2 Market Share by Region, 2029 & 2036 (%)

8 mRNA Cancer Vaccine Market Analysis by End-users
8.1 Key Findings
8.2 End Users Segment: Market Attractiveness Index
8.3 mRNA Cancer Vaccine Market Size Estimation and Forecast by End Users
8.4 Biopharma & Biotechnology Companies
8.4.1 Market Size by Region, 2026-2036 (US$ Million)
8.4.2 Market Share by Region, 2026 & 2036 (%)
8.5 Contract Development & Manufacturing Organizations (CDMOs)
8.5.1 Market Size by Region, 2026-2036 (US$ Million)
8.5.2 Market Share by Region, 2026 & 2036 (%)
8.6 Research Institutes & Academic Centers
8.6.1 Market Size by Region, 2026-2036 (US$ Million)
8.6.2 Market Share by Region, 2026 & 2036 (%)
8.7 Hospitals & Specialized Cancer Centers
8.7.1 Market Size by Region, 2026-2036 (US$ Million)
8.7.2 Market Share by Region, 2026 & 2036 (%)

9 mRNA Cancer Vaccine Market Analysis by Region
9.1 Key Findings
9.2 Regional Market Size Estimation and Forecast

10 North America mRNA Cancer Vaccine Market Analysis
10.1 Key Findings
10.2 North America mRNA Cancer Vaccine Market Attractiveness Index
10.3 North America mRNA Cancer Vaccine Market by Country, 2026, 2031 & 2036 (US$ Million)
10.4 North America mRNA Cancer Vaccine Market Size Estimation and Forecast by Country
10.5 North America mRNA Cancer Vaccine Market Size Estimation and Forecast by Indication
10.6 North America mRNA Cancer Vaccine Market Size Estimation and Forecast by Platform Type
10.7 North America mRNA Cancer Vaccine Market Size Estimation and Forecast by Therapeutic Approach
10.8 North America mRNA Cancer Vaccine Market Size Estimation and Forecast by Phases
10.9 North America mRNA Cancer Vaccine Market Size Estimation and Forecast by End Users
10.10 U.S. mRNA Cancer Vaccine Market Analysis
10.11 Canada mRNA Cancer Vaccine Market Analysis

11 Europe mRNA Cancer Vaccine Market Analysis
11.1 Key Findings
11.2 Europe mRNA Cancer Vaccine Market Attractiveness Index
11.3 Europe mRNA Cancer Vaccine Market by Country, 2026, 2031 & 2036 (US$ Million)
11.4 Europe mRNA Cancer Vaccine Market Size Estimation and Forecast by Country
11.5 Europe mRNA Cancer Vaccine Market Size Estimation and Forecast by Indication
11.6 Europe mRNA Cancer Vaccine Market Size Estimation and Forecast by Platform Type
11.7 Europe mRNA Cancer Vaccine Market Size Estimation and Forecast by Therapeutic Approach
11.8 Europe mRNA Cancer Vaccine Market Size Estimation and Forecast by Phases
11.9 Europe mRNA Cancer Vaccine Market Size Estimation and Forecast by End Users
11.10 Germany mRNA Cancer Vaccine Market Analysis
11.11 France mRNA Cancer Vaccine Market Analysis
11.12 UK mRNA Cancer Vaccine Market Analysis
11.13 Italy mRNA Cancer Vaccine Market Analysis
11.14 Spain mRNA Cancer Vaccine Market Analysis
11.15 Rest of Europe mRNA Cancer Vaccine Market Analysis

12 Asia Pacific mRNA Cancer Vaccine Market Analysis
12.1 Key Findings
12.2 Asia Pacific mRNA Cancer Vaccine Market Attractiveness Index
12.3 Asia Pacific mRNA Cancer Vaccine Market by Country, 2026, 2031 & 2036 (US$ Million)
12.4 Asia Pacific mRNA Cancer Vaccine Market Size Estimation and Forecast by Country
12.5 Asia Pacific mRNA Cancer Vaccine Market Size Estimation and Forecast by Indication
12.6 Asia Pacific mRNA Cancer Vaccine Market Size Estimation and Forecast by Platform Type
12.7 Asia Pacific mRNA Cancer Vaccine Market Size Estimation and Forecast by Therapeutic Approach
12.8 Asia Pacific mRNA Cancer Vaccine Market Size Estimation and Forecast by Phases
12.9 Asia Pacific mRNA Cancer Vaccine Market Size Estimation and Forecast by End Users
12.10 Japan mRNA Cancer Vaccine Market Analysis
12.11 China mRNA Cancer Vaccine Market Analysis
12.12 India mRNA Cancer Vaccine Market Analysis
12.13 Australia mRNA Cancer Vaccine Market Analysis
12.14 South Korea mRNA Cancer Vaccine Market Analysis
12.15 Rest of Asia Pacific mRNA Cancer Vaccine Market Analysis

13 Latin America mRNA Cancer Vaccine Market Analysis
13.1 Key Findings
13.2 Latin America mRNA Cancer Vaccine Market Attractiveness Index
13.3 Latin America mRNA Cancer Vaccine Market by Country, 2026, 2031 & 2036 (US$ Million)
13.4 Latin America mRNA Cancer Vaccine Market Size Estimation and Forecast by Country
13.5 Latin America mRNA Cancer Vaccine Market Size Estimation and Forecast by Indication
13.6 Latin America mRNA Cancer Vaccine Market Size Estimation and Forecast by Platform Type
13.7 Latin America mRNA Cancer Vaccine Market Size Estimation and Forecast by Therapeutic Approach
13.8 Latin America mRNA Cancer Vaccine Market Size Estimation and Forecast by Phases
13.9 Latin America mRNA Cancer Vaccine Market Size Estimation and Forecast by End Users
13.10 Brazil mRNA Cancer Vaccine Market Analysis
13.11 Mexico mRNA Cancer Vaccine Market Analysis
13.12 Rest of Latin America mRNA Cancer Vaccine Market Analysis

14 MEA mRNA Cancer Vaccine Market Analysis
14.1 Key Findings
14.2 MEA mRNA Cancer Vaccine Market Attractiveness Index
14.3 MEA mRNA Cancer Vaccine Market by Country, 2026, 2031 & 2036 (US$ Million)
14.4 MEA mRNA Cancer Vaccine Market Size Estimation and Forecast by Country
14.5 MEA mRNA Cancer Vaccine Market Size Estimation and Forecast by Indication
14.6 MEA mRNA Cancer Vaccine Market Size Estimation and Forecast by Platform Type
14.7 MEA mRNA Cancer Vaccine Market Size Estimation and Forecast by Therapeutic Approach
14.8 MEA mRNA Cancer Vaccine Market Size Estimation and Forecast by Phases
14.9 MEA mRNA Cancer Vaccine Market Size Estimation and Forecast by End Users
14.10 GCC mRNA Cancer Vaccine Market Analysis
14.11 South Africa mRNA Cancer Vaccine Market Analysis
14.12 Rest of MEA mRNA Cancer Vaccine Market Analysis

15 Company Profiles
15.1 Competitive Landscape, 2026
15.2 Strategic Outlook
15.3 Moderna, Inc.
15.3.1 Company Snapshot
15.3.2 Company Overview
15.3.3 Financial Analysis
15.3.3.1 Net Revenue, 2021-2025
15.3.3.2 R&D, 2021-2025
15.3.3.3 Regional Market Shares, 2025
15.3.3.4 Business Segment Market Shares, 2025
15.3.4 Product Benchmarking
15.3.5 SWOT Analysis
15.3.6 Strategic Outlook
15.4 BioNTech SE
15.4.1 Company Snapshot
15.4.2 Company Overview
15.4.3 Financial Analysis
15.4.3.1 Net Revenue, 2021-2025
15.4.3.2 R&D, 2021-2025
15.4.4 Product Benchmarking
15.4.5 SWOT Analysis
15.4.6 Strategic Outlook
15.5 Arcturus Therapeutics, Inc.
15.5.1 Company Snapshot
15.5.2 Company Overview
15.5.3 Financial Analysis
15.5.3.1 Net Revenue, 2021-2025
15.5.3.2 R&D, 2021-2025
15.5.3.3 Business Segment Market Shares, 2025
15.5.4 Product Benchmarking
15.5.5 SWOT Analysis
15.5.6 Strategic Outlook
15.6 etherna
15.6.1 Company Snapshot
15.6.2 Company Overview
15.6.3 Product Benchmarking
15.6.4 SWOT Analysis
15.6.5 Strategic Outlook
15.7 ETHRIS
15.7.1 Company Snapshot
15.7.2 Company Overview
15.7.3 Product Benchmarking
15.7.4 Strategic Outlook
15.8 ImmmuneSensor Therapeutics
15.8.1 Company Snapshot
15.8.2 Company Overview
15.8.3 Product Benchmarking
15.8.4 Strategic Outlook
15.9 Chimeron Bio
15.9.1 Company Snapshot
15.9.2 Company Overview
15.9.3 Product Benchmarking
15.9.4 Strategic Outlook
15.10 Replimune Group Inc.
15.10.1 Company Snapshot
15.10.2 Company Overview
15.10.3 Product Benchmarking
15.11 ST Pharm
15.11.1 Company Snapshot
15.11.2 Company Overview
15.11.3 Product Benchmarking
15.11.4 Strategic Outlook
15.12 Sana Biotechnology
15.12.1 Company Snapshot
15.12.2 Company Overview
15.12.3 Product Benchmarking
15.13 Cartesian Therapeutics Inc.
15.13.1 Company Snapshot
15.13.2 Company Overview
15.13.3 Financial Analysis
15.13.3.1 Net Revenue, 2021-2025
15.13.3.2 R&D, 2021-2025
15.13.4 Product Benchmarking
15.14 Strand Therapeutics
15.14.1 Company Snapshot
15.14.2 Company Overview
15.14.3 Product Benchmarking
15.14.4 Strategic Outlook
15.15 Acuitas
15.15.1 Company Snapshot
15.15.2 Company Overview
15.15.3 Product Benchmarking
15.15.4 Strategic Outlook

16 Conclusion and Recommendations
16.1 Concluding Remarks from Visiongain
16.2 Recommendations for Market Players

 

ページTOPに戻る



List of Tables/Graphs

List of Tables
Table 1 mRNA Cancer Vaccine Market Snapshot, 2026 & 2036 (US$ Million, CAGR %)
Table 2 mRNA Cancer Vaccine Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 3 mRNA Cancer Vaccine Market Forecast by Region 2026-2036 (US$ Million, AGR%, CAGR%), Tariff Impact: U- Shaped Recovery Scenario
Table 4 mRNA Cancer Vaccine Market Forecast by Region 2026-2036 (US$ Million, AGR%, CAGR%), Tariff Impact: L- Shaped Recovery Scenario
Table 5 mRNA Cancer Vaccine Market Forecast by Indication, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 6 High TMB Solid Tumors Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 7 GI Cancers Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 8 Gynecological Cancers Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 9 Breast Cancers Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 10 Other Sollid Tumors Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 11 mRNA Cancer Vaccine Market Forecast by Platform Type, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 12 Personalized Market Forecast by Platform Type, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 13 Off-the-Shelf Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 14 Semi-Personalized Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 15 mRNA Cancer Vaccine Market Forecast by Therapeutic Approach, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 16 Monotherapy Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 17 Combination Therapy Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 18 mRNA Cancer Vaccine Market Forecast by Phases, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 19 Phase I Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 20 Phase II Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 21 mRNA Cancer Vaccine Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 22 Phase IV Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 23 mRNA Cancer Vaccine Market Forecast by End Users, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 24 Biopharma & Biotechnology Companies Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 25 Contract Development & Manufacturing Organizations (CDMOs) Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 26 Research Institutes & Academic Centers Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 27 Hospitals & Specialized Cancer Centers Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 28 mRNA Cancer Vaccine Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 29 North America mRNA Cancer Vaccine Market Forecast by Country, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 30 North America mRNA Cancer Vaccine Market Forecast by Indication, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 31 North America mRNA Cancer Vaccine Market Forecast by Platform Type, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 32 North America mRNA Cancer Vaccine Market Forecast by Therapeutic Approach, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 33 North America mRNA Cancer Vaccine Market Forecast by Phases, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 34 North America mRNA Cancer Vaccine Market Forecast by End Users, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 35 U.S. mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 36 Canada mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 37 Europe mRNA Cancer Vaccine Market Forecast by Country, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 38 Europe mRNA Cancer Vaccine Market Forecast by Indication, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 39 Europe mRNA Cancer Vaccine Market Forecast by Platform Type, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 40 Europe mRNA Cancer Vaccine Market Forecast by Therapeutic Approach, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 41 Europe mRNA Cancer Vaccine Market Forecast by Phases, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 42 Europe mRNA Cancer Vaccine Market Forecast by End Users, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 43 Germany mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 44 France mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 45 UK mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 46 Italy mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 47 Spain mRNA Cancer Vaccine Market Forecast by Country, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 48 Rest of Europe mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 49 Asia Pacific mRNA Cancer Vaccine Market Forecast by Country, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 50 Asia Pacific mRNA Cancer Vaccine Market Forecast by Indication, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 51 Asia Pacific mRNA Cancer Vaccine Market Forecast by Platform Type, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 52 Asia Pacific mRNA Cancer Vaccine Market Forecast by Therapeutic Approach, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 53 Asia Pacific mRNA Cancer Vaccine Market Forecast by Phases, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 54 Asia Pacific mRNA Cancer Vaccine Market Forecast by End Users, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 55 Japan mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 56 China mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 57 India mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 58 Australia mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 59 South Korea mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 60 Rest of Asia Pacific mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 61 Latin America mRNA Cancer Vaccine Market Forecast by Country, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 62 Latin America mRNA Cancer Vaccine Market Forecast by Indication, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 63 Latin America mRNA Cancer Vaccine Market Forecast by Platform Type, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 64 Latin America mRNA Cancer Vaccine Market Forecast by Therapeutic Approach, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 65 Latin America mRNA Cancer Vaccine Market Forecast by Phases, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 66 Latin America mRNA Cancer Vaccine Market Forecast by End Users, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 67 Brazil mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 68 Mexico mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 69 Rest of Latin America mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 70 MEA mRNA Cancer Vaccine Market Forecast by Country, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 71 MEA mRNA Cancer Vaccine Market Forecast by Indication, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 72 MEA mRNA Cancer Vaccine Market Forecast by Platform Type, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 73 MEA mRNA Cancer Vaccine Market Forecast by Therapeutic Approach, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 74 MEA mRNA Cancer Vaccine Market Forecast by Phases, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 75 MEA mRNA Cancer Vaccine Market Forecast by End Users, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 76 GCC mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 77 South Africa mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 78 Rest of MEA mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 79 Strategic Outlook
Table 80 Moderna, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 81 Moderna, Inc.: Product Benchmarking
Table 82 Moderna, Inc.: SWOT Analysis
Table 83 Moderna, Inc.: Strategic Outlook
Table 84 BioNTech SE: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 85 BioNTech SE: Product Benchmarking
Table 86 BioNtech SE: SWOT Analysis
Table 87 BioNTech SE: Strategic Outlook
Table 88 Arcturus Therapeutics, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 89 Arcturus Therapeutics, Inc.: Product Benchmarking
Table 90 Arcturus Therapeutics, Inc.: SWOT Analysis
Table 91 Arcturus Therapeutics, Inc. : Strategic Outlook
Table 92 etherna: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 93 etherna: Product Benchmarking
Table 94 etherna: SWOT Analysis
Table 95 etherna: Strategic Outlook
Table 96 ETHRIS: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 97 ETHRIS: Product Benchmarking
Table 98 ETHRIS: Strategic Outlook
Table 99 ImmmuneSensor Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 100 ImmmuneSensor Therapeutics: Product Benchmarking
Table 101 ImmmuneSensor Therapeutics: Strategic Outlook
Table 102 Chimeron Bio: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 103 Chimeron Bio: Product Benchmarking
Table 104 Chimeron Bio: Strategic Outlook
Table 105 Replimune Group Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 106 Replimune Group Inc.: Product Benchmarking
Table 107 ST Pharm: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 108 ST Pharm: Product Benchmarking
Table 109 ST Pharm: Strategic Outlook
Table 110 Sana Biotechnology: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 111 Sana Biotechnology: Product Benchmarking
Table 112 Cartesian Therapeutics Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 113 Cartesian Therapeutics Inc.: Product Benchmarking
Table 114 Strand Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 115 Strand Therapeutics: Product Benchmarking
Table 116 Strand Therapeutics: Strategic Outlook
Table 117 Acuitas: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 118 Acuitas: Product Benchmarking
Table 119 Acuitas: Strategic Outlook

List of Figures
Figure 1 mRNA Cancer Vaccine Market Segmentation
Figure 2 mRNA Cancer Vaccine Market by Indication: Market Attractiveness Index
Figure 3 mRNA Cancer Vaccine Market by Platform Type: Market Attractiveness Index
Figure 4 mRNA Cancer Vaccine Market by End Users: Market Attractiveness Index
Figure 5 mRNA Cancer Vaccine Market Attractiveness Index by Region
Figure 6 mRNA Cancer Vaccine Market: Market Dynamics
Figure 7 mRNA Cancer Vaccine Market: Impact Analysis
Figure 8 mRNA Cancer Vaccine Market by Region, 2026-2036 (US$ Million, AGR %), Tariff Impact: V-Shaped Recovery Scenario
Figure 9 mRNA Cancer Vaccine Market by Region, 2026-2036 (US$ Million, AGR %), Tariff Impact: U-Shaped Recovery Scenario
Figure 10 mRNA Cancer Vaccine Market by Region, 2026-2036 (US$ Million, AGR %), Tariff Impact: L-Shaped Recovery Scenario
Figure 11 Short Term & Long Term Planning
Figure 12 Impact of U.S. and China Trade War
Figure 13 Most Impacted Countries
Figure 14 Global Market Tariff Sensitivity and Margin Pressure Analysis
Figure 15 mRNA Cancer Vaccine Market: Porter’s Five Forces Analysis
Figure 16 mRNA Cancer Vaccine Market: PEST Analysis
Figure 17 mRNA Cancer Vaccine Market by Indication: Market Attractiveness Index
Figure 18 mRNA Cancer Vaccine Market Forecast by Indication, 2026-2036 (US$ Million, AGR %)
Figure 19 mRNA Cancer Vaccine Market Share Forecast by Indication, 2026, 2031, 2036 (%)
Figure 20 High TMB Solid Tumors Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 21 High TMB Solid Tumors Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 22 GI Cancers Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 23 GI Cancers Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 24 Gynecological Cancers Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 25 Gynecological Cancers Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 26 Breast Cancers Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 27 Breast Cancers Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 28 Other Solid Tumors Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 29 Other Solid Tumors Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 30 mRNA Cancer Vaccine Market by Platform Type: Market Attractiveness Index
Figure 31 mRNA Cancer Vaccine Market Forecast by Platform Type, 2026-2036 (US$ Million, AGR %)
Figure 32 mRNA Cancer Vaccine Market Share Forecast by Platform Type, 2026, 2031, 2036 (%)
Figure 33 mRNA Cancer Vaccine Market Forecast by Platform Type, 2026-2036 (US$ Million, AGR %)
Figure 34 Personalized Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 35 Off-the-Shelf Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 36 Off-the-Shelf Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 37 Semi-Personalized Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 38 Semi-Personalized Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 39 mRNA Cancer Vaccine Market by Therapeutic Approach: Market Attractiveness Index
Figure 40 mRNA Cancer Vaccine Market Forecast by Therapeutic Approach, 2026-2036 (US$ Million, AGR %)
Figure 41 mRNA Cancer Vaccine Market Share Forecast by Therapeutic Approach, 2026, 2031, 2036 (%)
Figure 42 Monotherapy Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 43 Monotherapy Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 44 Combination Therapy Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 45 Combination Therapy Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 46 mRNA Cancer Vaccine Market by Phases: Market Attractiveness Index
Figure 47 mRNA Cancer Vaccine Market Forecast by Phases, 2026-2036 (US$ Million, AGR %)
Figure 48 mRNA Cancer Vaccine Market Share Forecast by Phases, 2026, 2031, 2036 (%)
Figure 49 Phase I Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 50 Phase I Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 51 Phase II Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 52 Phase II Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 53 Phase III Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 54 Phase III Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 55 Phase IV Segment Market Forecast by Region
Figure 56 Phase IV Segment Market Share Forecast by Region, 2029 & 2036 (%)
Figure 57 mRNA Cancer Vaccine Market by End Users: Market Attractiveness Index
Figure 58 mRNA Cancer Vaccine Market Forecast by End Users, 2026-2036 (US$ Million, AGR %)
Figure 59 mRNA Cancer Vaccine Market Share Forecast by End Users, 2026, 2031, 2036 (%)
Figure 60 Biopharma & Biotechnology Companies Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 61 Biopharma & Biotechnology Companies Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 62 Contract Development & Manufacturing Organizations (CDMOs) Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 63 Contract Development & Manufacturing Organizations (CDMOs) Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 64 Research Institutes & Academic Centers Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 65 Research Institutes & Academic Centers Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 66 Hospitals & Specialized Cancer Centers Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 67 Hospitals & Specialized Cancer Centers Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 68 mRNA Cancer Vaccine Market Forecast by Region 2026 and 2036 (Revenue, CAGR%)
Figure 69 mRNA Cancer Vaccine Market Share Forecast by Region 2026, 2031, 2036 (%)
Figure 70 mRNA Cancer Vaccine Market by Region, 2026-2036 (US$ Million, AGR %)
Figure 71 North America mRNA Cancer Vaccine Market Attractiveness Index
Figure 72 North America mRNA Cancer Vaccine Market by Region, 2026, 2031 & 2036 (US$ Million)
Figure 73 North America mRNA Cancer Vaccine Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
Figure 74 North America mRNA Cancer Vaccine Market Share Forecast by Country, 2026 & 2036 (%)
Figure 75 North America mRNA Cancer Vaccine Market Forecast by Indication, 2026-2036 (US$ Million, AGR %)
Figure 76 North America mRNA Cancer Vaccine Market Share Forecast by Indication, 2026 & 2036 (%)
Figure 77 North America mRNA Cancer Vaccine Market Forecast by Platform Type, 2026-2036 (US$ Million, AGR %)
Figure 78 North America mRNA Cancer Vaccine Market Share Forecast by Platform Type, 2026 & 2036 (%)
Figure 79 North America mRNA Cancer Vaccine Market Forecast by Therapeutic Approach, 2026-2036 (US$ Million, AGR %)
Figure 80 North America mRNA Cancer Vaccine Market Share Forecast by Therapeutic Approach, 2026 & 2036 (%)
Figure 81 North America mRNA Cancer Vaccine Market Forecast by Phases, 2026-2036 (US$ Million, AGR %)
Figure 82 North America mRNA Cancer Vaccine Market Share Forecast by Phases, 2026 & 2036 (%)
Figure 83 North America mRNA Cancer Vaccine Market Forecast by End Users, 2026-2036 (US$ Million, AGR %)
Figure 84 North America mRNA Cancer Vaccine Market Share Forecast by End Users, 2026 & 2036 (%)
Figure 85 U.S. mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 86 Canada mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 87 Europe mRNA Cancer Vaccine Market Attractiveness Index
Figure 88 Europe mRNA Cancer Vaccine Market by Region, 2026, 2031 & 2036 (US$ Million)
Figure 89 Europe mRNA Cancer Vaccine Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
Figure 90 Europe mRNA Cancer Vaccine Market Share Forecast by Country, 2026 & 2036 (%)
Figure 91 Europe mRNA Cancer Vaccine Market Forecast by Indication, 2026-2036 (US$ Million, AGR %)
Figure 92 Europe mRNA Cancer Vaccine Market Share Forecast by Indication, 2026 & 2036 (%)
Figure 93 Europe mRNA Cancer Vaccine Market Forecast by Platform Type, 2026-2036 (US$ Million, AGR %)
Figure 94 Europe mRNA Cancer Vaccine Market Share Forecast by Platform Type, 2026 & 2036 (%)
Figure 95 Europe mRNA Cancer Vaccine Market Forecast by Therapeutic Approach, 2026-2036 (US$ Million, AGR %)
Figure 96 Europe mRNA Cancer Vaccine Market Share Forecast by Therapeutic Approach, 2026 & 2036 (%)
Figure 97 Europe mRNA Cancer Vaccine Market Forecast by Phases, 2026-2036 (US$ Million, AGR %)
Figure 98 Europe mRNA Cancer Vaccine Market Share Forecast by Phases, 2026 & 2036 (%)
Figure 99 Europe mRNA Cancer Vaccine Market Forecast by End Users, 2026-2036 (US$ Million, AGR %)
Figure 100 Europe mRNA Cancer Vaccine Market Share Forecast by End Users, 2026 & 2036 (%)
Figure 101 Germany mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 102 France mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 103 UK mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 104 Italy mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 105 Spain mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 106 Rest of Europe mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 107 Asia Pacific mRNA Cancer Vaccine Market Attractiveness Index
Figure 108 Asia Pacific mRNA Cancer Vaccine Market by Region, 2026, 2031 & 2036 (US$ Million)
Figure 109 Asia Pacific mRNA Cancer Vaccine Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
Figure 110 Asia Pacific mRNA Cancer Vaccine Market Share Forecast by Country, 2026 & 2036 (%)
Figure 111 Asia Pacific mRNA Cancer Vaccine Market Forecast by Indication, 2026-2036 (US$ Million, AGR %)
Figure 112 Asia Pacific mRNA Cancer Vaccine Market Share Forecast by Indication, 2026 & 2036 (%)
Figure 113 Asia Pacific mRNA Cancer Vaccine Market Forecast by Platform Type, 2026-2036 (US$ Million, AGR %)
Figure 114 Asia Pacific mRNA Cancer Vaccine Market Share Forecast by Platform Type, 2026 & 2036 (%)
Figure 115 Asia Pacific mRNA Cancer Vaccine Market Forecast by Therapeutic Approach, 2026-2036 (US$ Million, AGR %)
Figure 116 Asia Pacific mRNA Cancer Vaccine Market Share Forecast by Therapeutic Approach, 2026 & 2036 (%)
Figure 117 Asia Pacific mRNA Cancer Vaccine Market Forecast by Phases, 2026-2036 (US$ Million, AGR %)
Figure 118 Asia Pacific mRNA Cancer Vaccine Market Share Forecast by Phases, 2026 & 2036 (%)
Figure 119 Asia Pacific mRNA Cancer Vaccine Market Forecast by End Users, 2026-2036 (US$ Million, AGR %)
Figure 120 Asia Pacific mRNA Cancer Vaccine Market Share Forecast by End Users, 2026 & 2036 (%)
Figure 121 Japan mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 122 China mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 123 India mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 124 Australia mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 125 South Korea mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 126 Rest of Asia Pacific mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 127 Latin America mRNA Cancer Vaccine Market Attractiveness Index
Figure 128 Latin America mRNA Cancer Vaccine Market by Region, 2026, 2031 & 2036 (US$ Million)
Figure 129 Latin America mRNA Cancer Vaccine Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
Figure 130 Latin America mRNA Cancer Vaccine Market Share Forecast by Country, 2026 & 2036 (%)
Figure 131 Latin America mRNA Cancer Vaccine Market Forecast by Indication, 2026-2036 (US$ Million, AGR %)
Figure 132 Latin America mRNA Cancer Vaccine Market Share Forecast by Indication, 2026 & 2036 (%)
Figure 133 Latin America mRNA Cancer Vaccine Market Forecast by Platform Type, 2026-2036 (US$ Million, AGR %)
Figure 134 Latin America mRNA Cancer Vaccine Market Share Forecast by Platform Type, 2026 & 2036 (%)
Figure 135 Latin America mRNA Cancer Vaccine Market Forecast by Therapeutic Approach, 2026-2036 (US$ Million, AGR %)
Figure 136 Latin America mRNA Cancer Vaccine Market Share Forecast by Therapeutic Approach, 2026 & 2036 (%)
Figure 137 Latin America mRNA Cancer Vaccine Market Forecast by Phases, 2026-2036 (US$ Million, AGR %)
Figure 138 Latin America mRNA Cancer Vaccine Market Share Forecast by Phases, 2026 & 2036 (%)
Figure 139 Latin America mRNA Cancer Vaccine Market Forecast by End Users, 2026-2036 (US$ Million, AGR %)
Figure 140 Latin America mRNA Cancer Vaccine Market Share Forecast by End Users, 2026 & 2036 (%)
Figure 141 Brazil mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 142 Mexico mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 143 Rest of Latin America mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 144 MEA mRNA Cancer Vaccine Market Attractiveness Index
Figure 145 MEA mRNA Cancer Vaccine Market by Region, 2026, 2031 & 2036 (US$ Million)
Figure 146 MEA mRNA Cancer Vaccine Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
Figure 147 MEA mRNA Cancer Vaccine Market Share Forecast by Country, 2026 & 2036 (%)
Figure 148 MEA mRNA Cancer Vaccine Market Forecast by Indication, 2026-2036 (US$ Million, AGR %)
Figure 149 MEA mRNA Cancer Vaccine Market Share Forecast by Indication, 2026 & 2036 (%)
Figure 150 MEA mRNA Cancer Vaccine Market Forecast by Platform Type, 2026-2036 (US$ Million, AGR %)
Figure 151 MEA mRNA Cancer Vaccine Market Share Forecast by Platform Type, 2026 & 2036 (%)
Figure 152 MEA mRNA Cancer Vaccine Market Forecast by Therapeutic Approach, 2026-2036 (US$ Million, AGR %)
Figure 153 MEA mRNA Cancer Vaccine Market Share Forecast by Therapeutic Approach, 2026 & 2036 (%)
Figure 154 MEA mRNA Cancer Vaccine Market Forecast by Phases, 2026-2036 (US$ Million, AGR %)
Figure 155 MEA mRNA Cancer Vaccine Market Share Forecast by Phases, 2026 & 2036 (%)
Figure 156 MEA mRNA Cancer Vaccine Market Forecast by End Users, 2026-2036 (US$ Million, AGR %)
Figure 157 MEA mRNA Cancer Vaccine Market Share Forecast by End Users, 2026 & 2036 (%)
Figure 158 GCC mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 159 South Africa mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 160 Rest of MEA mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 161 mRNA Cancer Vaccine Market: Company Share/Ranking, 2026
Figure 162 Moderna, Inc.: Net Revenue, 2021-2025 (US$ Billion, AGR%)
Figure 163 Moderna, Inc.: R&D, 2021-2025 (US$ Billion, AGR%)
Figure 164 Moderna, Inc.: Regional Market Shares, 2025
Figure 165 Moderna, Inc.: Business Segment Market Shares, 2025
Figure 166 BioNTech SE: Net Revenue, 2021-2025 (US$ Billion, AGR%)
Figure 167 BioNTech SE: R&D, 2021-2025 (US$ Billion, AGR%)
Figure 168 Arcturus Therapeutics, Inc.: Net Revenue, 2021-2025 (US$ Million, AGR%)
Figure 169 Arcturus Therapeutics, Inc.: R&D, 2021-2025 (US$ Million, AGR%)
Figure 170 Arcturus Therapeutics, Inc.: Business Segment Market Shares, 2025
Figure 171 Cartesian Therapeutics Inc.: Net Revenue, 2021-2025 (US$ Million, AGR%)
Figure 172 Cartesian Therapeutics, Inc.: R&D, 2021-2025 (US$ Million, AGR%)

 

　

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（医療/ヘルスケア）の最新刊レポート

Visiongain社の ヘルスケアと医薬・化学品分野 での最新刊レポート

本レポートと同じKEY WORD（cancer）の最新刊レポート


よくあるご質問


Visiongain社はどのような調査会社ですか?


英国の調査会社ヴィジョンゲイン社（Visiongain）は、通信とエネルギーのほか、自動車や化学・医薬品、金属など、広範な市場を対象に調査を行っています。自動車市場については、市場全般に関する調査のほ... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。


詳細検索

このレポートへのお問合せ

お問合せはこちらから

03-3582-2531

電話お問合せもお気軽に

 

当社ご利用のメリット
  1. ① お探しの情報に合わせてレポートをご紹介
  2. ② レポートで不足している情報はカスタマイズで対応可能
  3. ③ 特許情報、海外の法規制の取り組みなどディープな調査も対応可能
  4. ④ 円貨で請求書払い＆万全のアフターフォロー

 

2026/06/25　10:26

162.82 円

185.21 円

217.02 円

ページTOPに戻る

株式会社 データリソース　Data Resource, Inc.
東京都千代田区丸の内3-3-1 新東京ビル4F 430


A member of CORSS Business Producers Inc.
データリソースは2025年5月より
CROSS Business Producers株式会社 の100%子会社になりました。

電話：03-3582-2531
FAX：03-6551-2556
Eメール：office@dri.co.jp

会社概要 FAQ サイトマップ プライバシーポリシー お問合せ

関連会社:
株式会社ユーディーアール

COPYRIGHT(C) 2011-2025　DATA RESOURCE, Inc. ALL RIGHTS RESERVED.